60
Participants
Start Date
February 28, 2022
Primary Completion Date
June 30, 2024
Study Completion Date
January 31, 2025
JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody
Weekly infusion at the designated dose level until disease progression, withdrawal or up to two years
Pembrolizumab - anti-PD-1 antibody
200 mg, once every three weeks until disease progression, withdrawal or up to two years
RECRUITING
Wanfang Hospital -Taipei Medical University, Taipei
RECRUITING
Taipei Medical University -Shuang Ho Hospital, New Taipei City
Lead Sponsor
Shanghai Junshi Bioscience Co., Ltd.
OTHER
Anwita Biosciences
INDUSTRY